Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 871.00 | |
10 mg | Inquiry | $ 1,360.00 |
Description | IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1). |
Targets&IC50 | CDK7:≤50 nM (Ki), CDK2:≥1000 nM (Ki) |
In vitro | IV-361 demonstrates minimal inhibitory effects on CDK2 (K i ≥1000 nM) and PLK1 (K i ≥5000 nM), highlighting its specificity[1]. Moreover, it exhibits potent inhibition of IL-2 and IL-17 production (all IC 50 ≤100 nM) in peripheral blood mononuclear cells (PBMC), alongside significant growth inhibitory activity against HCT-116 cells (GI 50 ≤100 nM)[1]. |
In vivo | IV-361, administered orally at a dosage of 25 mg/kg/day, demonstrates a suppression rate of 46% or greater in tumor volume in female BALB/c nude mice implanted with HCT-116[1]. |
Molecular Weight | 457.625 |
Formula | C23H32FN5O2Si |
CAS No. | 2055741-39-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IV-361 2055741-39-2 Others IV 361 IV361 inhibitor inhibit